<DOC>
	<DOCNO>NCT02248259</DOCNO>
	<brief_summary>The objective current study evaluate effect daily itraconazole pharmacokinetics BI 409306 poor ( PM ) extensive metabolisers ( EM ) CYP2C19 .</brief_summary>
	<brief_title>Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor ( Itraconazole ) CYP2C19 Extensive Metabolizers Poor Metabolizers</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Inclusion criterion : Healthy CYP2C19 genotyped male volunteer accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR , respiratory rate , body temperature ) , 12lead ECG , ophthalmologic exam , clinical laboratory test Korean ethnicity accord follow criterion : current Korean passport national identification card holder , parent grandparent bear Korea Age 20 old 20 45 young 45 year BMI ( Body Mass Index ) 18.5 18.5 BMI 25 less 25 kg/m2 Signed date write informed consent prior admission study accordance GCP local legislation . Exclusion criterion : Any find medical examination ( include BP , PR , respiratory rate , body temperature ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy , hernia surgery ) Diseases central nervous system ( include limit kind seizure , migraine , stroke psychiatric disorder ) within past 6 month History relevant orthostatic hypotension , faint spell blackout . Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( long 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( 10 cigarette 3 cigar 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 20 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval 450 m ) A history additional risk factor Torsade de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) Abnormality color vision test find ophthalmologic exam clinically deem potentially interfere safety assessment trial Subjects agree minimize risk female partner become pregnant first dose day two month study completion . Acceptable method contraception comprise barrier contraception medically accept contraceptive method female partner ( intrauterine device spermicide , hormonal contraceptive since least two month )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>